From CNBC:

GlaxoSmithKline has raised its long-term outlook thanks to the success of its new RSV vaccine. The vaccine, which targets severe and life-threatening respiratory syncytial virus, generated around $1.5 billion in sales after being on the market for just six months. This success has pushed GSK to upgrade its growth outlooks for 2023, with forecasts of more than $48 billion in sales by 2031.

This success comes after the approval of Arexvy, the first-ever vaccines targeting respiratory syncytial virus, and has proven to be a boon for both GSK and Pfizer. Following its launch last year, Arexvy has gained regulatory approval in multiple countries and obtained a market share of about 70% for RSV, making it a major success for the company.

Pfizer also saw success with its RSV vaccine, known as Abrysvo, which garnered approximately $890 million in sales last year. The company is working on increasing its RSV market share and is looking into expanding its offerings and examining the shot in younger age groups, after initially describing the shot’s launch as “bad.”

On the horizon is Moderna’s plan to launch its own RSV vaccine, while the CDC has reported that RSV is responsible for thousands of deaths annually in the United States.



Read more: GSK posts blowout RSV vaccine sales, raises outlook